Editor's key points † Traditional opioid receptor classification conflicts with recent genetic knockout evidence, casting doubt over previous pharmacological evidence. † In this review, Dietis, Rowbotham, and Lambert examine the evidence for the existence of receptors and their subtypes and illustrate challenges and opportunities for future research.
Pharmacologically defined opioid receptor subtypes
As early as 1965, Portoghese 21 suggested that it may be necessary to propose the existence of more than one opioid receptor type or that multiple modes of interaction of ligands with opioid receptors were possible. Since then, and based on the pharmacology of a large number of opioid ligands, an equally large number of putative opioid receptor subtypes have been proposed. The first direct suggestions for the existence of opioid subtypes started with the m receptor, the main target for the production of clinical analgesia, 22 23 and this came about from the observations that some m ligands could differentially affect the analgesic response and the unwanted respiratory depression. These sites were named m 1 and m 2 receptors and are discussed in detail below. There is a vast amount of literature on pharmacological classification, thus we have been necessarily selective in coverage of the main ligands. Table 1 Proposed distribution, pharmacology and function of putative receptor subtypes of the MOP, DOP, and KOP receptors. TRIMU-5, [Tyr-D-Ala-Gly-NHC 2 H 4 CH(CH 3 )] 2 ; b-FNA, b-funaltrexamine; M6G, morphine-6-glucuronide; BNTX, 7-benzylidenenaltrexone; DPDPE, [D-Pen 2 ,D-Pen 5 ]-enkephalin; DSLET, D-Ser 2 -Leu-enkephalin-Thr 6 ; NalBzOH, naloxone-benzoyl-hydrazone; DALCE, [D-Ala 2 ,Leu 5 ,Cys 6 ]enkephalin; NO, nitric oxide; nor-BNI, norbinaltorphimine; 3-MTX, 3-methoxynaltrexone; 5-NTII, naltrindole-5 ′ -isothiocyanate. * shows lower affinity compared with the 'main' subtype. # Probable NOP; no evidence for NOP subtypes so not included in this Pharmacologically defined m-receptor subtypes Naloxonazine, b-funaltrexamine, TRIMU-5, and m 1 /m 2 Some of the first antagonists developed that could discriminate pharmacological m subtypes were naloxazone and naloxonazine (derivatives of naloxone), with the latter being more potent and more long acting. 24 25 In vivo, naloxonazine blocks morphine analgesia but does not significantly alter respiratory depression or gastrointestinal transit 26 27 or facial scratching. 28 Naloxonazine binding to the m 1 was irreversible and the m 2 reversible. 29 30 It was suggested that morphine bound with higher affinity to m 1 receptors to produce analgesia with lower affinity to a second site m 2 to produce sideeffects typical of m agonists. 26 -28 Moreover, there is evidence for site-related differences where Paul and colleagues 31 have provided evidence that naloxonazine blocks only the analgesia produced by supraspinally but not spinally administered morphine. On the other hand, the alkylating agent b-funaltrexamine (b-FNA) completely blocks spinal and supraspinal morphine analgesia. 31 32 A number of studies have suggested that the m opioid receptor is either sensitive or non-sensitive to b-FNA 33 34 and this may reveal m receptor heterogeneity. Indeed, we have used this compound to suggest that there were two populations of m receptor in the human neuroblastoma cell line SH-SY5Y. 35 TRIMU-5 (Tyr-D-Ala-Gly-NHC 2 H 4 CH(CH 3 ) 2 ) has been a particularly interesting ligand with proposed antagonist activity at the putative m 1 and agonist activity at the putative m 2 receptor subtype. 36 37 The interest in TRIMU-5 arises from the fact that it provides some evidence for communication between supraspinal and spinal m systems. A supraspinal, non-analgesic dose of TRIMU-5 antagonizes the analgesia produced by supraspinal morphine, an action that is thought to result from antagonism at m 1 . However, when the same dose of supraspinal TRIMU-5 was co-administered with spinal and supraspinal morphine in a synergy model, it potentiated analgesia, implying that (i) supraspinal m 1 receptor sites mediate supraspinal morphine analgesia and (ii) supraspinal m 2 receptor sites mediate interactions with spinal m opioid receptor systems. 37 A series of pharmacogenetic studies in mice of different strains (i.e. the same species with some genetic variation) have added weight to putative m receptor subtypes. Moskowitz and Goodman 38 have shown that the CXBK mice are deficient in putative m 1 sites. In later studies, different mice strains treated with a fixed dose of morphine (5 mg kg 21 s.c.) have shown wide differences in their analgesic sensitivity from 90% in BALB strain mice to 0% in CXBK mice. 39 40 The analgesic insensitivity of s.c. and supraspinal morphine in CXBK mice agrees with the m 1 deficiency seen by Moskowitz and Goodman. Pick and colleagues 37 have expanded this suggestion by showing a significant analgesic sensitivity of spinally administered morphine in CXBK mice. This implies that supraspinal and s.c. morphine do not have significant analgesic effects when putative m 1 receptor subtypes are not expressed in the brain.
Pharmacological m 3 receptor subtype
A third putative MOP subtype, m 3 , has also been described pharmacologically in various human tissues (neural, immune, vascular, gastrointestinal), where it is associated with a nitric oxide release pathway. The receptor is insensitive to opioid peptides but sensitive to opioid alkaloids. 41 -44 Morphine and naloxone display 20 and 10 times lower affinity for m 3 over m 1 sites, whereas the peptides Leu-enkephalin, Met-enkephalin, DAMGO, and DADLE did not interact with m 3 . 43 45 The putative m 3 cDNA, cloned in Cos-1 cells, expressed a receptor where a dose-dependent release of NO was produced in the presence of morphine. 43 Davis and colleagues 46 showed that b-FNA blocks the inducible nitric oxide synthase (iNOS) activity in human astroglial cells, by inhibiting its expression but the model expressed all opioid receptors. The exact mechanism of that inhibition is not clear.
Morphine-6-glucuronide receptor?
Morphine undergoes glucuronidation to morphine-6glucuronide (M6G) and morphine-3-glucuronide (M3G), with M6G being a potent antinociceptive ligand. 28 47 Andoh and colleagues have shown that analgesia is produced in mice after administration of intracisternal morphine and M6G, but not by M3G. In an interesting study, also in mice, Rossi and colleagues 48 showed that morphine-tolerant animals exhibited cross-tolerance to codeine but not to M6G, diamorphine or L-methadone and in rats, antisense oligonucleotides directed against the 5 ′ -untranslated region of m 1 blocks morphine but not M6G analgesia. 48 49 Knock-out of the single gene encoding MOP removes m receptor function.
Pharmacologically defined d-receptor subtypes
Pharmacological subtypes of the d receptor have been suggested with the main classification for putative subtypes being d 1 , d 2 and d complexed , d non-complexed . Most evidence is spinal and comes from mice. Of particular interest are the antagonists naltrindole 5 ′ -isothiocynate (5 ′ -NTII), naltriben, and 7-benzylidenenaltrexone (BNTX). 5 ′ -NTII reversed the analgesic effects of the d-agonist deltorphin-II but not the archetypal synthetic [D-Pen 2 5 ]enkephalin (DPDPE). 50 Naltriben and BNTX selectively blocked the effects of [D-Ser 2 ]-Leu-Enkephalin-Th (DSLET) and DPDPE, respectively. 51 Subsequently, d 1 receptor sites were classified as those activated by DPDPE and sensitive to BNTX where the d 2 receptor sites were activated by deltorphin-II and DSLET and sensitive to 5 ′ -NTII and naltriben. 52 More recently, Maslov 53 showed that the cardioprotective effects of deltorphin-II (putative d 2 agonist) were abolished by naltriben (putative d 2 antagonist), whereas putative d 1 antagonists were ineffective. Interestingly, Hirose and colleagues showed that DPDPE (putative d 1 agonist) and DSLET (putative d 2 agonist) significantly enhanced dopamine release from the nucleus accumbens of the rat in a dose-related manner. The effect of the former ligand was abolished by BNTX and the effect of the latter was abolished by naltriben. 51 In a study by Rawls and colleagues, 54 the DOP receptor agonist SNC-80 produced hypothermia that was blocked by naltriben but not BNTX, which, on face value, implicates putative d 2 receptor subtypes in thermoregulation. There is evidence (some covered here and also in our previous work) 55 to show an interaction of d with m (a receptor heterodimer); these are the putative d complexed receptor subtypes. 56 Knock-out of the single gene encoding DOP removes d receptor function.
Pharmacologically defined k-receptor subtypes
From a pharmacological perspective, the k receptor is more complex because there is evidence for k 1 , k 2 , and k 3 receptor subtypes 57 and further sub-division into k 1a and k 1b receptor sites 58 and also k 2a and k 2b sites. 59 There are a number of k ligands that have been used to come to these pharmacological conclusions. The main ligands include U69,593, U50,488H, and naloxone benzoylhydrazone (NalBzOH). Consensus seems to be that U69,593 discriminates k 1 sites, 60 61 whereas k 2 receptor subtypes are discriminated by difference 59 62 63 and k 3 sites are discriminated by NalBzOH and insensitivity to U50,488H. 58 Soon after the cloning of the k receptor, Pan and colleagues 64 used antisense oligonucleotide directed at the second extracellular loop of k 3 receptor subtypes in order to block NalBzOH-induced analgesia in mice. NalBzOH was initially thought to be a prototypic selective putative k 3 agonist 58 along with other actions at classical and non-classical opioid receptors. 65 Moreover, this is also questioned by Paul and colleagues, where they used nalorphine to selectively activate the k 3 receptor subtype. 66 Paul and colleagues showed peculiar nalorphine pharmacology, where in low doses, it antagonizes morphine analgesia, and at larger doses manifests analgesia by full agonism. This analgesia was naloxone-sensitive but b-FNA, naltrindole, and nor-BNI insensitive. However, this useful distinction has been questioned, and it is generally accepted that the k 3 receptor subtype is likely to be the NOP. 65 67 The pharmacological k 1 has been further subdivided based on differences seen with dynorphin A and U50,488H (proposed to bind to both k 1a and k 1b putative subtypes), and dynorphin-B and a-neoendorphin (proposed to be selective for the putative k 1b receptor). 58 Rothman and colleagues 61 investigated the pharmacological subdivision of the k 2 receptor subtype using leu-enkephalin as a selective antagonist of the k 2b site. Moreover, Nielsen and colleagues 59 proposed that oxycodone is a putative k 2b agonist. In this study, rats pretreated with i.c.v. nor-BNI (k antagonist) prevented i.c.v. oxycodone but not morphine antinociception. The opposite was shown with naloxonazine (putative m 1 antagonist), suggesting an oxycodone analgesic effect through KOP receptor binding. In addition, leu-enkephalin (proposed k 2b antagonist) prevented the displacement of [ 3 H]bremazocine by oxycodone. Further, in animals tolerant to i.v. morphine, Nielsen and colleagues 68 showed that there is an absence of antinociceptive crosstolerance to i.c.v. oxycodone. Interestingly, Nozaki and Kamei 69 showed that the antinociceptive effect of s.c. oxycodone in mice was completely antagonized by s.c. naloxonazine and only partially antagonized by s.c. nor-BNI. These studies imply a marked difference in the distribution of the putative k 2 receptor subtypes and possibly an interaction with m receptors at different sites (see later).
Knock-out of the single gene encoding KOP removes k receptor function.
Evidence for putative NOP receptor subtypes
The least amount of data are available regarding subtypes of NOP and this is not surprising as deorphanization of the receptor did not occur until 1995. 70 71 There were early suggestions of putative subtypes (central and peripheral), but most of these can be adequately explained by the nature of the ligands used, that is, they were partial agonists and central tissues in general had higher expression than peripheral tissues facilitating full agonist activity centrally. 72 -74 Interestingly, and in contrast to the classical opioid story described above, pharmacological and molecular (cloning) evidence were gathered side by side. There are published data for splice variants of NOP. For example, the short (truncated) form displays an unsurprising marked reduction in binding affinity for a range of NOP ligands and this is coupled with loss of function. 75 -78 There are some interesting new data in the periaqueductal grey (PAG) of the rat (which expresses NOP) where the Roche agonist Ro64 -6198 mimics the effects of N/OFQ in some but not all N/OFQsensitive neurones. However, we feel that these data can adequately be explained by the observation that Ro64-6198 is likely a partial agonist and that there is heterogeneous expression of NOP in the PAG. 79 80 The overriding piece of data (in complete agreement with the classical opioid receptors) is that in NOP-knockout animals, NOP pharmacology/function is absent. 81 -85 Can we reconcile the differences between the pharmacological and molecular evidence?
A simple count of the possible receptor subtypes gives 12 (classical and non-classical) (Fig. 1 ). Yet, knockout of each of the individual receptor subtypes removes all of the receptor function associated with that particular receptor. 81 82 84 86 -90 The logical conclusion of this rather simple statement is that there are only four opioid receptor types (m, d, k, and NOP), recognized by IUPHAR as MOP, DOP, KOP, and NOP (which, unless referring to the pharmacological subtypes, we will use for the remainder of this review). We would like to discuss three possible reconciliatory strategies for the pharmacological opioid receptor subtypes observed: (i) alternative splicing-splice variants, (ii) receptor dimerization, and (iii) a speculative interaction of a common opioid gene product with other proteins and ligand directed signalling.
Alternative splicing
A gene comprises introns (non-transcriptional genomic sequence) and exons (transcriptional sequence), where mRNA is produced by excluding the introns and placing the exons in tandem (Fig. 2, top) . Translation of the mRNA produces a functional protein. The MOP, DOP, and KOP mRNA include highly conserved regions, but also have differences in the exons translated for receptor production. 91 MOP mRNA is composed of exons 1, 2, 3, and 4; DOP mRNA is composed of exons 1, 2, and 3, whereas KOP mRNA is composed of exons 2, 3, and 4. 91 Alternative splicing occurs when, by various modes, the mRNAs produced from a single gene have differences in their exon composition and thus make up a different mRNA that will eventually produce a different (alternative) protein. 92 Alternative splicing is considered a mechanism used by cells in order to enhance protein (thus receptor) diversity, by simply using a single gene-template. Abnormal regulation of alternative splicing is also implicated in disease. 93 This mode of producing different proteins from a common gene product has been used in the opioid field in an attempt to explain subtypes. 94 The first real data came from the MOP gene where Zimprich and colleagues 95 identified an additional splice variant of the rat MOP (then called rMOR1B) which produced a receptor truncated at the Cterminus. In the absence of C-terminal phosphorylation sites, this receptor was relatively resistant to desensitization and hence functionally different from the 'normal' MOP receptor. Unfortunately, both variants bound naloxonazine equally and the authors concluded that these receptors Translation will process the mRNA to a functional protein (i.e. a receptor). The region of the mRNA that will or will not translate into a part of the protein is called the untranslated (UTR; shown as green) and translated region (TR; shown as blue) respectively. For source references, see text. were not m 1 and m 2 . Since the publication of this paper, the MOP receptor gene (OPRM1) has provided a large number of splice variants 32 42 96 -98 and it is beyond the scope of this review to cover all of these in detail. We have considered the OPRM1 gene in more detail in terms of three very general regions at the 5 ′ end coding the N-terminus in the 'middle' encoding the trans-membrane regions of the receptor and at the 3 ′ end encoding the C-terminus (Fig. 2) .
Opioid receptors
Considering first the N-terminus (i.e. targeted deletion of exon 11), this reduces opioid receptor density but does not affect ligand recognition at the expressed receptor. The analgesic response to M6G, heroin, fentanyl, and morphine, but not methadone, is reduced. 99 Splice variants affecting the transmembrane portion of the receptor are rare and we have already described that C-terminally truncated variants show loss of function and reduced desensitisation 95 (Fig. 2) .
Cadet and colleagues 41 proposed a correlation of an OPRM1 splice variant with the m 3 putative subtype. Compared with the OPRM1 mRNA, the variant contained a truncated mRNA 5 ′ end (hence a truncated exon-1 and different receptor N-terminus), and a unique exon at the mRNA 3 ′ end (hence longer receptor C-terminus), followed by a 202-nucleotides fragment of the OPRM1 untranslated region. When expressed in a heterologous system, the pharmacology of this variant was the same as that of the m 3 .
Interestingly, Schuller and colleagues 100 showed that although morphine analgesia was completely abolished in exon-1 knockouts, diamorphine and M6G analgesia were still present. These results strengthened the idea that variants of the MOP receptor lacking exon-1 are responsible for the residual activity of M6G and diamorphine. Antisense oligonucleotide targeting studies for exon-1 and -2 (i.e. down-regulation of mRNA) did not show similar effects for morphine, but they blocked the analgesic effects of M6G. 32 This is consistent with the suggestion that M6G and diamorphine may act through different receptor subtypes when compared with morphine (or bind with different affinities), or conversely, these receptors are splice variants.
In addition to receptor variations in terms of density, function, and desensitization profiles, regional differences should also be mentioned. Xu and colleagues 96 showed that in mouse, there is a differential expression of the receptor variants among brain regions. However, this expression could be at low levels. These data may be in line with regional differences seen in opioid receptor binding and activation, and also degrees of opioid tolerance seen in different tissues as observed by Xu and others. Pasternak 32 reports that some receptor variants differ greatly in distribution and localization with respect to the regular MOP receptor. For example, in the dorsal horn of the mouse spinal cord, there are cells expressing either MOP1 or MOP1C, but not both. Also, MOP1 is equally distributed pre-and post-synaptically, whereas MOP1C is distributed only presynaptically. Finally, MOP1C is always co-localized with calcitonin gene-related peptide (CGRP), whereas MOP1 is not. This example is characteristic for the distribution and localization of different splice variants and, although consistent with histological data, its biological significance is not entirely understood.
Opioid heterodimerization
Data that support the interaction between two opioid receptors have been the focus of intense activity since the late 1990s, in particular heterodimerization (i.e. the interaction of two different opioid receptor types). This interest was partially triggered by the large number of possible combinations arising from the four main (or primary) opioid subtypes (MOP, DOP, KOP, and NOP), and also by initial studies that proposed the behaviour of the heterodimer as a receptor entity with distinct pharmacology and differences in signalling mechanisms. 101 -105 Jordan and Devi 101 studied the DOP/KOP heterodimer, presenting the first pharmacological data of an opioid dimer and evidence for distinct pharmacology from the monomeric KOP or DOP receptor. Knock-out studies by Simonin and colleagues 90 have suggested that the putative k 2 receptor may represent mixed populations of MOP, DOP, and KOP receptors. Nielsen and colleagues 59 also suggested that the pharmacology seen with oxycodone may represent the binding and activation of an opioid receptor dimer, like the DOP/KOP. However, some less clear data have been generated when studying MOP/DOP dimers. Gomes and colleagues 106 provided evidence that MOP/DOP dimers possess functional and ligand binding synergy, whereas George and colleagues 102 showed a distinct binding profile of opioid ligands at MOP/DOP dimers. van Rijn 107 recently reviewed data for opioid receptor dimer trafficking, and some may be used to correlate with the properties seen of putative pharmacological subtypes. In another interesting recent study, Chakrabarti and colleagues 108 reported in vivo data indicating that MOP/KOP dimers are vastly more prevalent in the spinal cord of proestrous vs diestrous females and vs males and suggested MOP/KOP dimers as a female-specific pain target.
In Hirose and colleagues' 51 study of the inhibition of dopamine release via opioid receptor stimulation, mentioned in a previous section of this review, it was suggested that stimulation of MOP receptors activates putative d 1 receptor subtypes which in turn activate putative d 2 sites in nucleus accumbens, a suggestion that attempts to explain the gradual rise of extracellular dopamine after MOP activation. However, this implies either cross-communication of MOP and DOP systems or a direct interaction (i.e. dimerization).
There is also evidence for dimerization of the NOP receptor (described as k 3 in some of these papers). Pan and colleagues 109 demonstrated the presence of NOP -MOP dimers where some MOP ligands could displace [ 3 H]N/OFQ binding. Similar NOP-MOP dimers were described by Wang and colleagues 110 in which MOP signalling (cAMP formation) was reduced, perhaps providing a cellular basis for the anti-opioid actions of NOP. In a very recent and elegant study, Evans and colleagues 111 showed that NOP could dimerize with all (MOP, DOP, KOP) receptors and that activation of NOP causes internalization of all receptor types and interestingly MOP and NOP co-localize/internalize with Cav2.2 calcium channel.
Interaction of a common opioid gene product with other proteins
It is possible that the pharmacological subtypes could be explained based on differences in coupling to effector systems. There is evidence that opioid receptors are capable of coupling to G i/o and G s 108 112 -114 and we showed that MOP, DOP, and DOP were capable of coupling to phospholipase C to increase the production of Ins(1,4,5)P 3 . 115 116 However, the pharmacology of these responses did not yield many clues as to distinctly different receptor populations. There are differences in the way peptide and non-peptide MOP ligands induce receptor internalization, 117 but these have not been reconciled against putative m 1 or m 2 sites. Receptor dimerization between opioid and non-opioid receptors has also shown a number of combinations (KOP and b 2 -adrenoceptor, 104 DOP and a 1Aadrenoceptor), 118 and these may produce differences in pharmacological behaviour but are outside the scope of this review. A further potential explanation for existence of pharmacological receptor subtypes comes from the concept of functional selectivity or more correctly biased agonism. 119 This stems from the observations that ligands active at the same receptor are capable of producing different responses (i.e. the end response is biased depending on the ligand and signalling repertoire of the cell/tissue under consideration); there are compelling data in this context for the b-adrenoceptor. 120 So what about the opioid family? The seminal work of Whistler and von Zastrow 117 showed that etorphine but not morphine desensitized the MOP receptor (a biased response). Etorphine (and other ligands like fentanyl) produce high levels of phosphorylation and coupling to the arrestin pathway to produce desensitization; on the other hand, morphine appears to produce little MOP phosphorylation and couples to PKC1 to enhance ERK phosphorylation and hence desensitization. 121 In an elegant study using MOP mutants that blocked phosphorylation, Zheng and colleagues 122 recently demonstrated that etorphine (and fentanyl) now behaved like morphine. Similar agonist biased responses have been reported for the DOP receptor where SNC80 and ARM390 (DOP ligands with similar antinociceptive actions) produced different desensitization responses; SNC80 desensitized but ARM390 did not. Following chronic treatment, SNC80 reduced receptor density and ARM390 resulted in uncoupling of Ca 2+ channels. 123 So can this give any clues to subtypes? The work in this area is still at an early stage and we cannot be firm here, but it will be interesting to use some of the discriminatory ligands in Table 1 (especially antagonists) to probe for differential antagonism of any biased agonist response.
We would like to end this section with some very speculative thoughts. Consider the calcitonin receptor-like receptor (CRLR-a class B GPCR; opioids are class A). When CRLR associates with receptor activity modifying protein (RAMP) isoform-1, it becomes a CGRP receptor but when it interacts with RAMP-2 or -3, it becomes an adrenomedullin receptor. 124 As a provocative thought what would common MOP (or DOP/KOP) gene product behave like if associated with similar modifying proteins?
Conclusions
Putative opioid receptor subtypes are suggested mainly by: (i) different modulation by pharmacological agents of functional responses (in vivo, ex vivo, and in vitro); (ii) an incomplete cross-tolerance profile between different receptor agonists; (iii) complex binding characteristics including: shallow ligand displacement curves and differential irreversibility of ligand binding. However, these suggestions must be set beside the molecular evidence of (i) only single receptor encoded by a single gene and (ii) genetic knockout of the single receptor gene results in a loss of ligand binding and function associated with that receptor. That there are physiological, pharmacological, and behavioural differences with ligands of different classes is not in doubt, but we do not believe that, based on these differences, receptor subtype status can be ascribed. Moreover, there is at least one example of possible misclassification (putative k 3 is likely to be NOP).
We believe that these pharmacological subtypes can be reconciled with the molecular data by considering (i) alternative splicing, (ii) receptor dimerization, (iii) interaction with other proteins and biased agonism, and (iv) combinations of (i) -(iii) (Fig. 3 ).
We will finish by trying to answer the question 'Opioid receptors: fact or artifact?'; variations in ligand activity along with MOP, DOP, KOP, and NOP are a fact. As for the artifact, that is for the reader to decide, but we do not believe that subtype status can be ascribed. What is clear is that assigning variations in ligand activity to one or more of the molecular suggestions represents one of the future directions for opioid research. 
